Study on ATX-898 for Adults with Advanced Solid Tumors

Inclusion Criteria

• Have a confirmed diagnosis of advanced solid tumor that cannot be surgically removed and has spread.
• Be 18 years or older.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have good organ function based on medical tests.
• Agree to provide a tumor sample before starting treatment.

For Part 1a (testing ATX-898 alone):

• Have tried at least one standard cancer treatment, and no other standard treatments are available or suitable.

For Part 1b (expanding ATX-898 alone):

• b1: Have ovarian cancer that does not respond to platinum-based treatments.
• b2: Have recurrent or metastatic gynecologic cancer, excluding those in b1.
• b3: Have recurrent advanced or metastatic solid tumor, excluding those in b1 or b2.
• Have at least one measurable tumor.

For Part 2a (testing ATX-898 with other drugs):

• Have hormone receptor-positive, HER2-negative cancer (including low and ultra-low HER2 levels).
• Have received prior treatment for metastatic cancer.

For Part 2b (expanding ATX-898 with other drugs):

• Have hormone receptor-positive, HER2-negative cancer (including low and ultra-low HER2 levels).
• Either have not been treated or have received prior treatment for metastatic cancer.

Exclusion Criteria

• Have had a different type of cancer within the last 2 years.
• Have cancer that has spread to the brain and is causing symptoms or requires steroids to manage symptoms.
• Have side effects from previous cancer treatments that have not improved, except for hair loss or mild nerve damage.
• Have any condition that the study doctor believes would make participation unsafe or interfere with the study.

Cohort Specific:

• For those taking abemaciclib: Have a history of heart problems that would prevent taking abemaciclib.
• For those taking ribociclib: Have a history of lung inflammation or lung disease.